Maple Capital Management’s AbbVie ABBV Stock Holding History

Maple Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$827K	Sell	3,801 -90	-2%	-$20K	0.06%	59
2025 Q4	$889K	Sell	3,891 -31	-0.8%	-$7.06K	0.06%	59
2025 Q3	$908K	Hold	3,922	–	–	0.06%	56
2025 Q2	$728K	Buy	3,922 +493	+14%	+$91.6K	0.05%	65
2025 Q1	$718K	Buy	3,429 +1,092	+47%	+$212K	0.06%	65
2024 Q4	$415K	Buy	2,337 +497	+27%	+$91.4K	0.03%	83
2024 Q3	$363K	Sell	1,840 -225	-11%	-$42K	0.03%	87
2024 Q2	$354K	Buy	2,065 +5	+0.2%	+$828	0.03%	92
2024 Q1	$375K	Sell	2,060 -107	-5%	-$18.4K	0.03%	82
2023 Q4	$336K	Buy	2,167 +805	+59%	+$117K	0.03%	79
2023 Q3	$203K	Buy	+1,362	New	+$200K	0.02%	94
2023 Q1	–	Sell	-1,284	Closed	-$208K	–	98
2022 Q4	$208K	Sell	1,284 -77	-6%	-$11.8K	0.03%	92
2022 Q3	$207K	Buy	+1,361	New	+$195K	0.03%	89
2022 Q2	–	Sell	-1,361	Closed	-$221K	–	92
2022 Q1	$221K	Buy	+1,361	New	+$198K	0.03%	95
2015 Q4	–	Sell	-84,817	Closed	-$4.62M	–	127
2015 Q3	$4.62M	Sell	84,817 -2,960	-3%	-$193K	1.71%	23
2015 Q2	$5.9M	Sell	87,777 -1,449	-2%	-$94.6K	2.02%	18
2015 Q1	$5.22M	Buy	89,226 +43,828	+97%	+$2.65M	1.82%	22
2014 Q4	$2.97M	Buy	45,398 +1,048	+2%	+$66.1K	1.08%	38
2014 Q3	$2.56M	Sell	44,350 -1,125	-2%	-$62.5K	0.97%	40
2014 Q2	$2.57M	Sell	45,475 -710	-2%	-$37.2K	0.93%	44
2014 Q1	$2.37M	Sell	46,185 -1,303	-3%	-$65.9K	0.92%	44
2013 Q4	$2.51M	Sell	47,488 -500	-1%	-$24.6K	1%	40
2013 Q3	$2.15M	Sell	47,988 -2,930	-6%	-$130K	0.95%	41
2013 Q2	$2.1M	Buy	+50,918	New	+$2.23M	0.94%	43

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maple Capital Management's ABBV Position: Q1 2026 in Review

Maple Capital Management reduced its AbbVie (ABBV) stake by 2.3% in Q1 2026, selling an estimated $20K and leaving 3,801 shares worth $827K. The position accounts for 0.06% of the portfolio, ranked #59.

Maple Capital Management first reported a position in ABBV in Q2 2013 and has held it in 24 quarters since. The position peaked at $5.9M in Q2 2015. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Maple Capital Management held 3,801 shares of AbbVie worth $827K as of Q1 2026.
Maple Capital Management sold 90 AbbVie shares in Q1 2026, an estimated $20K.
AbbVie made up 0.06% of Maple Capital Management's portfolio in Q1 2026, its #59 holding.
Maple Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 24 quarters since.
Maple Capital Management's AbbVie position peaked at $5.9M in Q2 2015.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Maple Capital Management's 13F filing for Q1 2026, filed 8 May 2026.